Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge
Abstract The outbreak of Monkeypox virus infection urgently need effective vaccines. However, the vaccines so far approved are all based on whole-virus, which raises safety concerns. MRNA vaccines has demonstrated its high efficacy and safety against SARS-Cov-2 infection. Here, we developed three mRNA vaccines encoding Monkeypox proteins M1R and A35R, including A35R-M1R fusions (VGPox1 and VGPox 2) and a combination of encapsulated full-length mRNAs for A35R and M1R (VGPox 3). All three vaccines induced anti-A35R total IgGs as early as day 7 following a single vaccination. However, only VGPox 1 and 2 produced anti-M1R total IgGs at early dates following vaccination while VGPox 3 did not show significant anti-M1R antibody till day 35. Similar results were also found in neutralizing antibodies and T cell immune response. However, all mRNA vaccine groups completely protected mice from a lethal dose virus challenge and effectively cleared virus in lungs. Collectively, our results indicate that the novel mRNA vaccines coding for a fusion protein of A35R and M1R had a better anti-virus immunity than co-expression of the two individual proteins. The mRNA vaccines are highly effective and can be an alternative to the current whole-virus vaccines to defend Monkeypox virus infection..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 24. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hou, Fujun [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.11.19.517190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037934392 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037934392 | ||
| 003 | DE-627 | ||
| 005 | 20230429094139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221122s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.11.19.517190 |2 doi | |
| 035 | |a (DE-627)XBI037934392 | ||
| 035 | |a (biorXiv)10.1101/2022.11.19.517190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hou, Fujun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The outbreak of Monkeypox virus infection urgently need effective vaccines. However, the vaccines so far approved are all based on whole-virus, which raises safety concerns. MRNA vaccines has demonstrated its high efficacy and safety against SARS-Cov-2 infection. Here, we developed three mRNA vaccines encoding Monkeypox proteins M1R and A35R, including A35R-M1R fusions (VGPox1 and VGPox 2) and a combination of encapsulated full-length mRNAs for A35R and M1R (VGPox 3). All three vaccines induced anti-A35R total IgGs as early as day 7 following a single vaccination. However, only VGPox 1 and 2 produced anti-M1R total IgGs at early dates following vaccination while VGPox 3 did not show significant anti-M1R antibody till day 35. Similar results were also found in neutralizing antibodies and T cell immune response. However, all mRNA vaccine groups completely protected mice from a lethal dose virus challenge and effectively cleared virus in lungs. Collectively, our results indicate that the novel mRNA vaccines coding for a fusion protein of A35R and M1R had a better anti-virus immunity than co-expression of the two individual proteins. The mRNA vaccines are highly effective and can be an alternative to the current whole-virus vaccines to defend Monkeypox virus infection. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Zhang, Yuntao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaohu |e verfasserin |4 aut | |
| 700 | 1 | |a Murad, Yanal |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zhibin |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Xianwu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Hongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ronghua |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, William |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaoming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 24. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:24 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.11.19.517190 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 24 |c 11 | ||